Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Veterans Health topic
No spam. Unsubscribe anytime.
Panel backs fund to explore psychedelic‑assisted ‘breakthrough’ therapies for veteran suicide prevention
Summary
SB 1101 would establish a fund and council to support clinical trials, training and patient access for FDA breakthrough‑designated psychedelic‑assisted therapies targeted at veterans with PTSD and treatment‑resistant conditions. The subcommittee reported the bill after supporters — including veteran advocates and medical
The subcommittee reported SB 1101, which would create a Breakthrough Therapies for Veteran Suicide Prevention fund to support clinical trials, patient access programs and training related to FDA breakthrough‑designated therapies, including MDMA‑assisted therapy for PTSD and psilocybin‑based therapies for treatment‑resistant depression.
Sponsor remarks: Sen. Hashmi said veterans have disproportionately high suicide risk and that emerging research shows some breakthrough psychedelic‑assisted therapies may offer rapid, durable benefit for treatment‑resistant conditions. The bill proposes a dedicated fund, a coordinating council and mechanisms to support clinical trials and clinician training.
Testimony: Lisonbee Messick of the Navy SEAL Foundation and other veteran advocates supported the bill, saying traditional medications frequently do not relieve symptoms and that research investment could deliver new options. Supporters noted FDA breakthrough‑therapy designations for some MDMA and psilocybin trials and cited preliminary efficacy in controlled settings.
Opposition and concerns: No formal opposition was recorded at the hearing. Committee members asked questions about program timing and implementation; a member recorded an abstention on the report vote but otherwise the bill was advanced.
Committee action: The subcommittee voted to report the bill to the next committee; the clerk recorded four yes votes and one abstention (one entry recorded as an abstention by proxy). Sponsor and supporters signaled they will supply additional enactment language and implementation details.
Why it matters: The bill seeks to create state support infrastructure for clinical and training capacity around promising but still‑investigational therapies for high‑risk veterans, with the aim of reducing suicide and improving outcomes for treatment‑resistant conditions.
Next steps: The subcommittee recommended reporting the bill to the next committee and asked sponsors to provide additional implementation details and fiscal estimates.
